TRIM35 and hepatocellular carcinoma: Simultaneously, TRIM35 inhibits the tumorigenicity of HCC cells by blocking PKM2 Y105 (tyrosine residue 105) phosphorylation, because PKM2 has been demonstrated to have a central role in metabolic reprogramming after it is up-regulated by phosphorylation of PKM2 Y105 during cancer progression [82].